[89Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer.

Academic Article

Abstract

  • PURPOSE: The purpose of the present study is to evaluate safety, human radiation dosimetry, and optimal imaging time of [89Zr]trastuzumab in patients with HER2-positive breast cancer. PROCEDURES: Twelve women with HER2-positive breast cancer underwent [89Zr]trastuzumab positron emission tomography (PET)/X-ray computed tomography (CT) twice within 7 days post-injection. Biodistribution data from whole-torso PET/CT images and organ time-activity curves were created using data from all patients. Human dosimetry was calculated using OLINDA with the adult female model. RESULTS: High-quality images and the greatest tumor-to-nontumor contrast were achieved with images performed 5 ± 1 day post-injection. Increased [89Zr]trastuzumab uptake was seen in at least one known lesion in ten patients. The liver was the dose-limiting organ (retention of ∼12 % of the injected dose and average dose of 1.54 mSv/MBq). The effective dose was 0.47 mSv/MBq. No adverse effects of [89Zr]trastuzumab were encountered. CONCLUSION: [89Zr]trastuzumab was safe and optimally imaged at least 4 days post-injection. The liver was the dose-limiting organ.
  • Authors

    Published In

    Keywords

  • Dosimetry, HER2, PET imaging, Trastuzumab, Zirconium-89, Adult, Aged, Breast Neoplasms, Female, Humans, Middle Aged, Positron Emission Tomography Computed Tomography, Radioisotopes, Radiometry, Receptor, ErbB-2, Time Factors, Tissue Distribution, Trastuzumab, Zirconium
  • Digital Object Identifier (doi)

    Authorlist

  • Laforest R; Lapi SE; Oyama R; Bose R; Tabchy A; Marquez-Nostra BV; Burkemper J; Wright BD; Frye J; Frye S
  • Start Page

  • 952
  • End Page

  • 959
  • Volume

  • 18
  • Issue

  • 6